
Sign up to save your podcasts
Or
The approval of antibody-drug conjugate Tivdak (tisotumab vedotin) for treating cervical cancer and the future of Genmab A/S are the subjects with the company's president and CEO, Jan van de Winkel.
Hosted on Acast. See acast.com/privacy for more information.
5
11 ratings
The approval of antibody-drug conjugate Tivdak (tisotumab vedotin) for treating cervical cancer and the future of Genmab A/S are the subjects with the company's president and CEO, Jan van de Winkel.
Hosted on Acast. See acast.com/privacy for more information.
38,603 Listeners
30,676 Listeners
32,120 Listeners
4,200 Listeners
86,708 Listeners
110,863 Listeners
55,895 Listeners
316 Listeners
9,266 Listeners
86 Listeners
30 Listeners
5,477 Listeners
15,513 Listeners
18 Listeners
39 Listeners